85-2065-26　Gastrointestinal Cancer Antigen (CA 19-9) 10KU　208910

特徴

• CA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category. It was discovered in patients with colon cancer and pancreatic cancer in 1981. Increased levels of CA19-9 are also found in non-malignant conditions, such as Mirizzi's syndrome and diseases of the bile ducts and liver. The molecular weight of CA19-9 of the patients with pancreas carcinoma was ~2000kD, however those of the patients with liver disorder and diabetes mellitus were showed 2000kD and round 700kD
• The assay for Pancreatic and Gastro-Intestinal Cancer marker (PC-199) measures a carbohydrate antigenic determinant expressed on a high molecular weight mucin. This mucin type of glycoprotein is found in the area of pancreatic and colon and hepatocellular carcinomas. PC 19-9 (CA 199) is also related to the Lewis blood group substances and only serum antigen from cancer patients belonging to the Le (a+b-) or Le (ab+) blood group will be CA 19-9 positive
• The Pancreatic & Gastro-Intestinal (PC) assay may have two clinical applications:1. To identify patients having gastric and pancreatic carcinomas
• 2. To monitor therapy and tumor recurrence
• Source:CA19-9/CA199 antigen, from human fluids tested negative for HIV 1, HIV 2, HCV antibodies, HIV antigen and HBsAg.
• Contaminants:CA125: <2%CA15-3: <1%
• Activity:~150,000 units/ml (Centocor RIA) or ~125,000 units/ml (Elecsys)
• Protein:~59000 U/ml (Elecsys 19-9 assay; Protein conc ~0.052OD units)
• Applications:Suitable for use in RIA and Western Blot. Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.